Introduction {#Sec1}
============

Cardiovascular (CV) disease remains the principal cause of death worldwide, with three-fourths of CV deaths attributed to atherosclerosis. Pathological studies in patients who have died from coronary heart disease (CHD) show extensive evidence of coronary atherosclerosis \[[@CR1]\]. The current paradigm suggests that the main cause of cardiac death is primarily due to rupture of an advanced atherosclerotic lesion \[[@CR2]\]. Ruptured plaques contain the largest amount of necrotic core (NC) among atherosclerotic lesions, suggesting a link between the amount of NC and their predisposition to rupture \[[@CR3]\]. In fact, the area of necrotic core in thin capped fibroatheromas (TCFA) is 1.6 ± 1.8 mm^2^ and in ruptured plaques is 2.2 ± 1.9 mm^2^ respectively \[[@CR3]\].

Anthropometric measurements and conventional CV risk factors relate to the risk of subsequent CV events as demonstrated by the original Framingham cohort, and more recently by the INTERHEART multi-ethnic study on the predictors of the first myocardial infarction (MI) \[[@CR4], [@CR5]\]. Notwithstanding these observations, accurate prediction of major coronary events on an individual patient level, as opposed to population based studies, remains challenging. Therefore, there is an interest in additional markers of patient vulnerability that would enhance precision of risk estimation beyond that afforded by the Framingham risk score or other conventional risk assessment tools. The ability to quantify NC in vivo by the intravascular ultrasound radiofrequency (IVUS-RF) data analysis offers the opportunity to provide unique information about plaque type to enhance the precision of clinical and laboratory variables used to assess CV risk. Although the ultimate validity of this measurement will require very large and long-term natural history studies, the first step is to examine the relationship between patient derived variables and NC and extension of coronary atheroma. Accordingly, we sought to explore in vivo the relationship between patient demographics, anthropometric measures, CV risk factors, soluble biomarkers and plaque composition (percentage of necrotic core) or its overall size (percentage atheroma volume).

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The Integrated Biomarkers and Imaging Study-2 trial has been published elsewhere \[[@CR6]\]. Briefly, it was an international, multicenter, randomized, double blind, placebo-controlled study in patients with confirmed CHD. Institutional review boards at each center approved the protocol, and patients provided written informed consent. Within 10 days of cardiac catheterization, eligible patients who were clinically stable were randomized to oral doses of darapladib EC 160 mg (GlaxoSmithKline) or placebo once daily (1:1 ratio) for the 12 months treatment period.

Patient population {#Sec4}
------------------

Patients 18 years of age or older undergoing cardiac catheterization for acute coronary syndrome (ACS---non-ST-elevation and ST-elevation MI) or non-ACS (e.g, chronic stable angina or troponin-negative resting chest pain) were eligible. The protocol specified that 50% of randomized patients were to have troponin-positive ACS. The randomization was stratified according to ACS status and center. Key exclusion criteria were planned surgical revascularization, stroke in the past 6 months, chronic hepatic disorder or abnormal ALT, bilirubin (ALT \> 2.5 or bilirubin \> 1.5 upper limit of normal), serum creatinine \> 2.0 mg/dL, blood pressure \> 160/100 mmHg, poorly controlled diabetes mellitus (HbA~1c~ \> 10%), severe heart failure or left ventricular ejection fraction \<30%, and current life-threatening condition. Patients were ineligible if angiography demonstrated left main coronary stenosis \>50% or if coronary anatomy was inappropriate for IVUS.

IVUS imaging {#Sec5}
------------

The ECG-gated IVUS-RF acquisition was performed using EagleEye catheter (20 MHz) at pullback speed of 0.5 mm/sec. The quantitative IVUS analysis was performed by the Core Imaging Laboratory (Cardialysis, Rotterdam, The Netherlands) using customized software (pcVH 2.1, Volcano Corporation). The analyst selected the region of interest flanked by the presence of easily identifiable anatomical landmarks.

Vessel and lumen area data were obtained for every cross-section throughout the region of interest by semiautomatic planimetry of the leading edges of the luminal and external elastic membrane borders. The composition of coronary atheroma was assessed using spectral analysis of backscatter RF signals (Fig. [1](#Fig1){ref-type="fig"}). Necrotic core was identified with an autoregressive classification system that showed a sensitivity and specificity of 92 and 97% for detection of necrotic core, respectively. To assess intra- and inter-observer variability of necrotic core measurements, 20 patients from the current study (2,465 frames) were analyzed twice by two different analysts. The mean absolute difference for necrotic core area was 0.01 mm^2^ (SD 0.06) for the intra-observer, and 0.02 mm^2^ (SD 0.08) for the inter-observer variability, respectively.Fig. 1The ultrasound signal is generated in a piezoelectric crystal (*asterisk*) that transmits and receives sound waves (**a**). Ultrasound reflected by the tissue deforms crystal generating radiofrequency (RF) signal (**b**). Greyscale IVUS is derived from the amplitude of RF signal, discarding information beneath the peaks of the signal (**c**). Changes in the electric field of the piezoelectric crystal caused by ultrasound reflection is used to generate a grey-tone image (**d**). IVUS-RF analysis uses several additional spectral parameters to identify four plaque components (**e**). Plaque components that are identified are dense calcium (*white*), fibrous (*green*), fibro-fatty (*greenish-yellow*) and necrotic core (*red*) (**f**). *PAV* percentage atheroma volume, *EEM* external elastic membrane, *CSA* cross-sectional area

Study end point definitions (IVUS-RF) {#Sec6}
-------------------------------------

*Atheroma area* contains both atherosclerotic plaque and media. This was obtained after planimetry was completed at the lumen/plaque boundary and at the media/adventitia boundary in each cross-section forming the region of interest. Percent atheroma volume was derived by dividing the total atheroma volume by the total vessel volume and multiplying by 100.

*The necrotic core area* was automatically obtained in each cross-section forming the region of interest using dedicated software (pcVH 2.1, Volcano Therapeutics). Necrotic core values were expressed in mm^2^. In addition, the percentage of necrotic core was calculated as the percentage of the total tissue type components.

Biomarkers {#Sec7}
----------

Plasma hsCRP was measured as described previously \[[@CR7]\]. Plasma Lp-PLA~2~ activity was measured by a colorimetric method \[[@CR7]\]. Other biomarkers (IL-6, MPO, ICAM-1, and MMP-9 activity) were assayed using commercially available kits. Oxidized phospholipid content per particle of apoB (oxPL/apoB) was measured using murine monoclonal antibody E06 as described \[[@CR8]\]. Platelet biomarkers were measured in plasma (P-selectin, CD40L) \[[@CR7]\].

Endothelial function {#Sec8}
--------------------

Endothelial function was assessed using peripheral artery tonometry (PAT). PAT is a noninvasive method that uses automated technology to obtain continuous data monitoring of the peripheral arterial pulse waveform by use a finger-mounted pneumatic sensor (Endo-PAT 2000, Itamar Medical). The magnitude of the waveform is dependent on vascular compliance. Endothelial function is assessed by changes in compliance after period of ischemia followed by reperfusion. A ratio of the amplitude prior and after occlusion is calculated and corrected for baseline value and a second sensor is used as a control on the non-occluded extremity.

Statistical analysis {#Sec9}
--------------------

Necrotic core as a percent of VH plaque and percent atheroma volume (both baseline and change from baseline) were the dependent variables explored in these analyses. A total of 39 covariates were considered in the univariate regression analyses. In addition, treatment group and baseline value were considered in the analyses of change from baseline. All class variables, except gender, were coded \[0,1\] with 0 for absence or 1 for presence. Gender was coded 0 for females and 1 for males. The set of variables with a *p* value of ≤0.10 in the univariate regression analyses were included in the multivariate regression analyses. Both backward selection and forward selection were used, and the entry criterion and stay criterion were set to 0.05.

Statistical analyses were performed with use of SAS V9.1.3.

Results {#Sec10}
=======

Between November 16th, 2005 and August 16th, 2006, 330 patients were enrolled.

There are 239 subjects with a value for change from baseline in % necrotic core and there are 262 subjects with a value for change from baseline in % atheroma volume. Table [1](#Tab1){ref-type="table"}, which has been published previously characterizes the population and is based on the ITT population (N = 323) \[[@CR6]\]. Mean length of the IVUS pullbacks was 50.3 ± 16.8 mm.Table 1Baseline CharacteristicsPlacebo (n = 151)Darapladib (n = 172)Clinical characteristics Age (y)57.3 ± 10.959.4 ± 9.8 Males (n, %)126 (83)140 (81) Body-mass index (kg/m^2^)27.8 ± 3.827.5 ± 4.0 Diabetes mellitus (n, %)22 (15)22 (13) Hypertension (n, %)89 (59)115 (67) Low HDL cholesterol (\<40 mg/dL) (n, %)40 (26)45 (26) Hypercholesterolemia (n, %)95 (63)108 (63)Current smoker (n, %) Prior medical history (n, %)57 (38)64 (37) Prior myocardial infarction49 (32)51 (29) Prior coronary revascularization47 (31)50 (29) Peripheral artery disease7 (5)17 (10) Prior stroke3 (2)4 (2)Index hospitalization (n, %) ACS74 (49)87 (51)  STEMI35 (23)40 (23)  Non-STEMI39 (26)47 (27) PCI during index hospitalization122 (81)130 (76)Cardiovascular medications at randomization (n, %) Aspirin138 (91)149 (87) Clopidogrel or ticlopidine122 (81)136 (79) Any antiplatelet medication150 (\> 99)170 (99) ACE inhibitors or ARBs88 (58)101 (59) Beta-blockers119 (79)138 (80) Statins134 (89)157 (91)Laboratory values Cholesterol (mg/dL)  Total187.3 ± 47.6182.3 ± 43.2  LDL108.2 ± 41.4103.6 ± 37.4  HDL46.8 ± 11.248.0 ± 12.4 Triglycerides (mg/dL)  Median141136  IQR97--20296--193 hsC-reactive protein (mg/L)  geometric mean2.42.4  95% CI1.9, 3.11.9, 3.0 Lp-PLA~2~ activity (μmol/min/L)  geometric mean159160  95% CI152, 167153, 167 Blood pressure Systolic (mm Hg)125.7 ± 16.9128.0 ± 16.1 Diastolic (mmHg)75.2 ± 10.175.6 ± 9.9Study vessel^a^--no. (%) LAD44 (36)56 (39) LCX32 (26)37 (26) RCA45 (37)51 (35) Diameter stenosis^b^ (%)28.0 (10.5)26.6 (10.3)Mean lumen diameter^b^ (mm)2.9 ± 0.53.0 ± 0.6Values are presented as mean ± SD unless otherwise specified; To convert to mmol/L multiply values of cholesterol by 0.02586 and triglycerides by 0.0113*PCI* percutaneous coronary intervention, *ACS* acute coronary syndromes^a^Imaging evaluable population: placebo 121 patients; darapladib 146 patients^b^Quantitative coronary angiography: placebo 121 patients; darapladib 144 patients

Univariate association between baseline characteristics and plaque morphology {#Sec11}
-----------------------------------------------------------------------------

The list of variables (only those with a *p* value \< 0.10) and their univariate association with percentage necrotic core (PNC) area and percentage atheroma volume (PAV) is shown in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}.Table 2List of variables (only with a *p* value \< 0.10) and their univariate association with percentage necrotic coreParameterParameter estimate 90% CI*p* value*Cross-sectional analysis at baseline--percentage necrotic core*Waist circumference0.063 (0.003, 0.123)0.085Netherlands/Belgium4.733 (2.143, 7.323)0.003Czech Republic/Poland4.030 (1.351, 6.708)0.014Germany/Austria/Denmark3.775 (1.010, 6.540)0.025Norway4.244 (0.770, 7.718)0.045Spain3.975 (0.337, 7.612)0.072GFR \< 602.429 (0.020, 4.838)0.097Systolic blood pressure0.047 (0.006, 0.087)0.057Hypercholesterolemia−1.474 (−2.825, −0.122)0.073Creatinine (nlog)5.758 (2.717, 8.799)0.002Mean lumen diameter−2.449 (−3.755, −1.144)0.002Myeloperoxidase−0.932 (−1.773, −0.091)0.068P*redictors of change from baseline--percentage necrotic core*ACS−1.961 (−3.791, −0.132)0.078Statin−3.196 (−6.084, −0.309)0.069Previous stroke6.040 (0.191, 11.888)0.090oxPL(n log)1.191 (0.026, 2.355)0.093Circulating p-selection (n log)−2.935 (−5.340, −0.529)0.045Previous PCI or CABG2.211 (0.269, 4.154)0.061% Diameter stenosis0.103 (0.014, 0.191)0.057Baseline % necrotic core−0.561 (−0.677, −0.445)\<0.001Darapladib−2.038 (−3.872, −0.204)0.068Table 3List of variables (only with a *p* value \< 0.10) and their univariate association with percentage atheroma volumeParameterParameter estimate 90% CI*p* value*Cross-sectional analysis at baseline--percentage atheroma volume*Age0.240 (0.140, 0.339)\<0.001Smoking−3.718 (−5.790, −1.646)0.003ACS−3.733 (−5.735, −1.731)0.002GFR \< 605.541 (1.612, 9.470)0.021SBP (0.110 (0.047, 0.173)0.004IL-6 (n log)1.103 (0.107, 2.099)0.069OxPL (n log)1.550 (0.251, 2.850)0.050HbA1c (n log)15.075 (6.445, 23.705)0.004Previous PCI or CABG4.770 (2.634, 6.905)0.003Creatinine (n log)6.720 (1.950, 11.491)0.021% Diameter stenosis0.335 (0.245, 0.426)\<0.001Endothelial function3.721 (0.856, 6.587)0.033MMP-9 (n log)−1.331 (−2.630, −0.031)0.092P*redictors of change from baseline--percentage atheroma volume*Waist circumference−0.048 (−0.085, −0.012)0.031Czech Republic/Poland2.933 (1.250, 4.616)0.004Statin use−2.156 (−3.509, −0.803)0.009CD40L (n log)−0.776 (−1.294, −0.257)0.014DBP0.078 (0.037, 0.119)0.002Myeloperoxidase (n log)0.529 (0.014, 1.043)0.091Baseline % atheroma volume−0.095 (−0.135, −0.056)\<0.001*GFR* Glomerular filtration rate, *oxPL* Oxidized phospholipids, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass graft, *ACS* acute coronary syndrome, *SBP* systolic blood pressure, *IL* interleukin, *HbA1c* Hemoglobin A1c, *MMP* Matrix metalloproteinase, *DBP* diastolic blood pressure

Multivariate association between baseline characteristics and plaque morphology {#Sec12}
-------------------------------------------------------------------------------

In the multivariate analysis, at baseline, creatinine had a positive, whereas baseline mean lumen diameter and myeloperoxidase a negative, independent association with PNC. Age, GFR \< 60, HbA1c, previous percutaneous or surgical coronary revascularisation and baseline % diameter stenosis were all positively associated with baseline PAV, whilst ACS had a negative association (Table [4](#Tab4){ref-type="table"}).Table 4List of variables (*p* ≤ 0.05) and their multivariate association with percentage necrotic core and percentage atheroma volumeParameter*p* value estimate (95% CI)Variable*Cross-sectional analysis at baseline--percentage necrotic core*Creatinine (μmol/L--n log)5.7 (1.8, 9.6)0.004Mean lumen diameter (mm)−2.3 (−3.8, −0.79)0.003Myeloperoxidase (n log)−1.2 (−2.2, −0.15)0.025*Predictors of change from baseline--percentage necrotic core*Darapladib−2.1 (−4.0, −0.22)0.029Acute coronary syndrome−2.9 (−4.8, −1.0)0.003Previous stroke8.4 (2.6, 14.2)0.005Baseline % diameter stenosis0.10 (0.007, 0.19)0.035Baseline % NC−0.56 (−0.69, −0.42)\<0.001*Cross-sectional analysis at baseline--percentage atheroma volume*Age (y)0.12 (0.001, 0.24)0.049Acute coronary syndrome−2.6 (−4.9, −0.29)0.027GFR \< 60 ml/min5.1 (0.90, 9.3)0.017HbA1c (n log)12.4 (2.9, 21.9)0.011Previous PCI or CABG3.1 (0.66, 5.6)0.013Baseline % diameter stenosis0.33 (0.22, 0.44)\<0.001*Predictors of change from baseline--percentage atheroma volume*Waist circumference (cm)−0.05 (−0.09, −0.004)0.032Statin Use−2.0 (−3.6, −0.42)0.013CD40L (pg/ml)−0.74 (−1.3, −0.15)0.014Diastolic blood pressure (mmHg)0.09 (0.04, 0.14)\<0.001Baseline % atheroma volume−0.09 (−0.14, −0.04)\<0.001

Multivariate association between baseline characteristics and change from baseline in plaque morphology {#Sec13}
-------------------------------------------------------------------------------------------------------

The variables associated with a decreased PNC from baseline were darapladib, ACS and a large content of NC at baseline, while variables associated with an increase in PNC were previous stroke and % diameter stenosis at baseline. The variables associated with a decrease in PAV from baseline were waist circumference, statin use, CD40L and baseline PAV, while the only variable associated with an increase in PAV was diastolic blood pressure (Table [4](#Tab4){ref-type="table"}).

Discussion {#Sec14}
==========

In non-culprit vessels, large baseline and necrotic core rich plaques are associated with a decrease in percentage of necrotic core at 1 year. Patients with acute coronary syndrome are more likely to have a decrease in necrotic core. In this analysis, and after adjustment for other variables, treatment with darapladib was associated with a decrease in necrotic core, but failed to be associated with a decrease in percentage atheroma volume. On the contrary, statin use was only associated with a decrease in percentage atheroma volume. Thus, patients may need to receive both drugs to target overall plaque regression and specifically necrotic core regression.

Our current understanding of plaque biology suggests that \~60% of clinically evident plaque rupture (i.e. acute coronary syndromes) originates within an inflamed thin-capped fibroatheroma (TCFA) \[[@CR9]\]. TCFAs are coronary plaques that contain the largest necrotic core. In living patients, Hong et al. reported the frequency and distribution of TCFA identified by virtual histology intravascular ultrasound in acute coronary syndrome (ACS = 105 pts) and stable angina pectoris (SAP = 107 pts) in a 3-vessel IVUS-VH study. There were 2.5 ± 1.5 in ACS and 1.7 ± 1.1 in SAP TCFAs per patient, *p* \< 0.001. Presentation with ACS was the only independent predictor for multiple IVUS derived-TCFA (*p* = 0.011). Thus, in patients with ACS not only are necrotic core rich plaques more likely to be present, but they are also present in higher numbers when compared to patients with stable angina.

A pathological study has shown that Lp-PLA2 staining was nearly absent in pathologic intimal thickening plaques; while in complex lesions, such as thin-cap fibroatheromas and ruptured plaques, an intense Lp-PLA2 expression within necrotic cores and surrounding macrophages, including those in the fibrous cap, was seen \[[@CR10]\]. In animal studies, reduced development of advanced coronary atherosclerosis has been seen in diabetic and hypercholesterolemic swine with the use of selective lipoprotein-associated phospholipase A2 inhibitors (i.e. darapladib) \[[@CR11]\]. Specifically, darapladib treatment resulted in a considerable decrease in plaque area and necrotic core area, and reduced medial destruction, resulting in fewer lesions with an unstable phenotype.

Necrotic core and cardiovascular risk factors in pathological studies {#Sec15}
---------------------------------------------------------------------

Prior attempts to correlate patient characteristics with plaque morphology assessed during post-mortem examination are limited by selection bias, (only patients with fatal events due to coronary or no coronary causes are included) and often post-mortem ascertainment of laboratory values. Nevertheless, history of smoking was associated with evidence of acute coronary thrombosis (OR 3.6, *p* = 0.004) whilst low HDL-cholesterol levels were associated with plaque rupture (odds ratio for each additional milligram per deciliter, 1.01) \[[@CR12]\]. Diabetes was shown to be associated with larger necrotic core and increased macrophage content consistent with the clinically observed increased risk of CV events in these patients \[[@CR13]\]. The differences with the current study may stem from the fact that our observations focused on non-culprit vessels. In addition, the current algorithm for spectral analysis of IVUS-RF is unable to detect thrombus and lacks precision to detect inflammatory cell content. Post-mortem measurement of HDL-cholesterol is also fraught with potential confounding factors.

Plaque size by intravascular imaging and its relationship with CV risk factors {#Sec16}
------------------------------------------------------------------------------

Several CV risk factors such as male gender, body mass index (BMI), diabetes and prior coronary revascularization have been found to be strong predictors of atheroma volume measured by conventional IVUS. As shown by Nicholls et al. atheroma volume in women in secondary prevention trials is smaller, even in the presence of more risk factors \[[@CR14]\]. Our study confirms some of these observations showing an independent association of HbA1C and prior coronary revascularization with IVUS measurements. Diabetes *per se* was not an independent predictor and this is possibly related to the low number of diabetics enrolled in the current study. Obesity is an important but complex contributor to CV morbidity and mortality \[[@CR15]\]. Waist circumference, and simple measures of visceral (abdominal) obesity, has a superior predictive value for the presence of CHD or the risk of MI, compared to that of BMI \[[@CR16]\]. The large multi-ethnic INTERHEART study showed a significant relationship between waist circumference or waist-to-hip ratio and the risk of first MI, even after full adjustment for other risk factors \[[@CR5]\]. Furthermore, patients with low BMI and increased waist circumference have an increased 1-year mortality \[[@CR17]\]. In our study, patients with large waist circumference were independently associated with percentage atheroma volume reduction after 1 year.

Despite favourable effects of cholesterol-lowering therapy with statins in primary and secondary prevention, a single measurement of serum lipids did not correlate with IVUS measurements of percentage atheroma volume or percentage necrotic core in univariate or multivariate analysis. These findings are consistent with those reported by others regarding conventional IVUS measures and do not contradict halting plaque progression or even its regression with intensive LDL cholesterol lowering.

In contrast to lipid measurements, renal dysfunction was related to both larger percentage necrotic core and larger percentage atheroma volume. Anavekar et al. \[[@CR18]\] have described that even mild renal disease should be considered a major risk factor for cardiovascular complications after an MI. We could hypothesize that the underlying cause of these events are necrotic core-rich large plaques.

It is noteworthy that diastolic blood pressure was shown to be independently associated with plaque progression by IVUS, and therapeutic intervention(s) aimed at lowering blood pressure below current guideline mandated thresholds, may retard progression of atherosclerosis and reduce CV events \[[@CR19]\].

Study limitations {#Sec17}
-----------------

This study is a post-hoc analysis that has a number of limitations. First, the sample size was small. Second, the measurements of biomarkers that entered into the model do not reflect chronic circulating levels, as 50% of patients presented with ACS, which transiently alters levels of inflammatory biomarkers. In addition, our data indicate that ACS status is not associated with necrotic core size when assessed in non-culprit vessels. Although pan-coronary inflammation was reported in ACS patients, IVUS methodology is not well suited to measure such endpoints. Third, some of the measurements are confounded by concomitant treatments. Fourth, we wish to emphasize that all IVUS studies are limited to the analysis of a relatively short segment of coronary arterial tree that does not fully reflect disease characteristics elsewhere.

Although independently treatment with darapladib was associated with a decrease in percentage necrotic core and statin use was only associated with a decrease in percentage atheroma volume, the interaction factor between statins and darapladib for the relationship between changes in necrotic core and percentage atheroma volume has not been assessed.

Conclusions {#Sec18}
===========

In non-culprit vessels, large baseline and necrotic core rich plaques are associated with a decrease in percentage of necrotic core at 1 year. Patients with acute coronary syndrome are more likely to have a decrease in necrotic core. In these analyses and after adjustment for other variables, treatment with darapladib was associated with a decrease in percentage necrotic core, but failed to be associated with a decrease in percentage atheroma volume. On the contrary, statin use was only associated with a decrease in percentage atheroma volume.
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Appendix {#Sec19}
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Core Laboratories: Imaging (Cardialysis, Rotterdam, The Netherlands).

Participating Centers (number of patients enrolled): Austria: Hanusch Krankenhaus, Georg Gaul (6). Belgium: Centre Hospitalier Universitaire Sart-Tilman, Victor Legrand (10); ZNA Campus Middelheim, Stefan Verheye (25); Cardiovascular Center, Aalst, William Wijns (14). Czech Republic: Všeobecná Fakultní Nemocnice, Michael Aschermann (23). Denmark: Skejby University Hospital, Hans Erik Bøtker (18). Germany: West German Heart Center, Raimund Erbel (7); Kerckhoff Klinik, Christian Hamm (7); Universitätsklinikum Heidelberg, Stefan Hardt, Helmut Kücherer (1); Universitätsklinikum München, Volker Klauss (14), Universitätsklinikum Ulm, Wolfgang Koenig (9); Segeberger Kliniken, Gert Richardt (3). The Netherlands: Medisch Spectrum Twente, Clemens von Birgelen (14); Medisch Centrum Leeuwarden, Adrianus Johannes van Boven (12); Catharina Hospital and Catherine R&D, Herman Rolf Michels (14), Erasmus Medical Center, Patrick Serruys (20); Medisch Centrum Rijnmond Zuid, Pieter Smits (11). Norway: Haukeland Sykehus, Oyvind Bleie (20). Poland: Upper Silesian Heart Center, Pawel Buszman (40); Szpital Uniwersytecki, Dariusz Dudek (19). Spain: Hospital Marques de Valdecilla, Thierry Colman (9); Hospital Clinico San Carlos, Carlos Macaya (9). Switzerland: Kantonsspital Luzern, Paul Erne (25).

For the IBIS-2 Investigators.
